Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study.
Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: studnicka m. Strahlenther Onkol. 2007 Dec;183 Spec No 2:38-40. doi: 10.1007/s00066-007-2015-4. Strahlenther Onkol. 2007. PMID: 18167008 No abstract available.
Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: studnicka m. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1345-51. doi: 10.1016/j.ijrobp.2009.06.060. Epub 2009 Nov 10. Int J Radiat Oncol Biol Phys. 2010. PMID: 19910140 Clinical Trial.
DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K, Deutschmann H, Dagn K, Kopp P, Zehentmayr F, Lamprecht B, Porsch P, Wegleitner B, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: studnicka m. Radiat Oncol. 2013 Mar 5;8:49. doi: 10.1186/1748-717X-8-49. Radiat Oncol. 2013. PMID: 23497555 Free PMC article.
Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F, Söhn M, Exeli AK, Wurstbauer K, Tröller A, Deutschmann H, Fastner G, Fussl C, Steininger P, Kranzinger M, Belka C, Studnicka M, Sedlmayer F. Zehentmayr F, et al. Among authors: studnicka m. Radiat Oncol. 2015 May 28;10:121. doi: 10.1186/s13014-015-0429-1. Radiat Oncol. 2015. PMID: 26018527 Free PMC article.
DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K, Zehentmayr F, Deutschmann H, Dagn K, Exeli AK, Kopp P, Porsch P, Maurer B, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: studnicka m. Strahlenther Onkol. 2017 Apr;193(4):315-323. doi: 10.1007/s00066-016-1095-4. Epub 2017 Jan 23. Strahlenther Onkol. 2017. PMID: 28116446 Free PMC article. Clinical Trial.
163 results